FDA Approves Novocure’s Optune Lua for Metastatic NSCLC Treatment

1 November 2024
Novocure, a prominent global oncology company, has announced that the U.S. Food and Drug Administration (FDA) has granted approval for Optune Lua®, a pioneering treatment for adult patients with metastatic non-small cell lung cancer (mNSCLC) that has advanced following a platinum-based regimen. This innovative therapy can now be administered in conjunction with PD-1/PD-L1 inhibitors or docetaxel, marking a significant step forward in mNSCLC treatment.

Optune Lua is a portable device that utilizes alternating electric fields, known as Tumor Treating Fields (TTFields), to combat cancer cells. The mechanism involves physical forces exerted on the electrically charged components of dividing cancer cells, leading to cell death. This non-invasive, wearable treatment offers a novel approach to managing mNSCLC, particularly for patients who have seen disease progression after initial therapies.

The recent approval follows promising results from the Phase 3 LUNAR trial, which demonstrated a notable improvement in median overall survival for patients using Optune Lua. The trial, which was prospective, randomized, and open-label, included multiple centers and compared the efficacy of Optune Lua when used alongside PD-1/PD-L1 inhibitors or docetaxel to the use of these treatments alone. The primary endpoint of the study was met, showing a median overall survival extension of 3.3 months for patients treated with Optune Lua in combination with either PD-1/PD-L1 inhibitors or docetaxel compared to those receiving the latter therapies alone.

Specifically, patients treated with Optune Lua and a PD-1/PD-L1 inhibitor had a median overall survival of 19.0 months, significantly longer than the 10.8 months observed in patients treated with PD-1/PD-L1 inhibitors alone. Similarly, the subgroup that received Optune Lua with docetaxel experienced a median overall survival of 11.1 months, compared to 8.9 months for those on docetaxel alone.

The LUNAR study also highlighted the safety profile of Optune Lua, indicating that most device-related adverse events were manageable and primarily skin-related, with no occurrences of grade 4 or 5 toxicities. These findings underscore the potential benefits of integrating TTFields therapy into the treatment regimen for mNSCLC, offering a new avenue for patients and healthcare providers seeking more effective options.

Dr. Ticiana Leal, Associate Professor and Director of the Thoracic Oncology Program at the Winship Cancer Institute of Emory University School of Medicine and primary investigator of the LUNAR study, emphasized the significance of these findings. She noted that despite advances in first-line treatments for NSCLC, many patients eventually experience disease progression and face limited options beyond initial therapies. The observed improvement in overall survival with Optune Lua, coupled with its lack of systemic toxicity, represents a compelling development for this challenging patient population.

Danielle Hicks, Chief Patient Officer at GO2 for Lung Cancer, echoed this sentiment, highlighting the urgent need for new treatment options in the fight against lung cancer. The approval of Optune Lua provides hope for patients and underscores the continuous efforts to advance lung cancer treatments.

Non-small cell lung cancer (NSCLC) is the most prevalent form of lung cancer, accounting for about 85% of cases. It remains a leading cause of cancer-related deaths globally. Treatment strategies for NSCLC vary based on the disease stage and typically involve a combination of surgery, radiation, and pharmacological therapies. For advanced stages, platinum-based chemotherapy has been the standard first-line treatment since 1991. However, the landscape is rapidly evolving with the introduction of immune checkpoint inhibitors.

Optune Lua's approval marks a significant milestone for Novocure, reflecting its commitment to developing innovative cancer therapies. By providing a non-invasive treatment option that can be combined with existing therapies, Optune Lua has the potential to significantly impact the lives of patients with metastatic NSCLC. As research and clinical trials continue, this approval represents a promising step forward in the ongoing effort to improve cancer treatment outcomes.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!